Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Myelodysplastic Syndrome Specialty Channel

Myelodysplastic Syndrome
Specialty Channel
News
FDA Grants Approval to Imetelstat for Patients With Low to Intermediate-1 Risk Myelodysplastic Syndrome With Transfusion-Dependent Anemia
06/21/2024
The FDA granted approval to imetelstat for patients with low to intermediate-1 risk MDS with transfusion-dependent anemia requiring 4 or more red blood cell transfusion units over 8 weeks, who cannot derive benefit from...
The FDA granted approval to imetelstat for patients with low to intermediate-1 risk MDS with transfusion-dependent anemia requiring 4 or more red blood cell transfusion units over 8 weeks, who cannot derive benefit from...
The FDA granted approval to...
06/21/2024
Oncology
Quiz
Safety of Oral Decitabine Cedazuridine vs Intravenous Decitabine for Patients With MDS or CML
06/02/2024
06/02/2024
Oncology
News
Azacitidine Maintenance Demonstrates Lower Disease Progression Rate Among Patients With High-Risk FLT3-Negative AML/MDS
03/05/2024

Amber Denham

Amber Denham
According to a retrospective analysis, azacitidine maintenance is associated with a lower progression rate in patients with high-risk FLT3-negative acute myeloid leukemia or myelodysplastic syndrome.
According to a retrospective analysis, azacitidine maintenance is associated with a lower progression rate in patients with high-risk FLT3-negative acute myeloid leukemia or myelodysplastic syndrome.
According to a retrospective...
03/05/2024
Oncology
News
Oral Decitabine Cedazuridine Safe, Effective Alternative to Intravenous Decitabine for Patients With MDS or CML
02/21/2024

Amber Denham

Amber Denham
Oral decitabine cedazuridine demonstrates safety and efficacy as an alternative to intravenous decitabine treatment among patients with myelodysplastic syndromes or chronic myelomonocytic leukemia, according to phase 3 study results.
Oral decitabine cedazuridine demonstrates safety and efficacy as an alternative to intravenous decitabine treatment among patients with myelodysplastic syndromes or chronic myelomonocytic leukemia, according to phase 3 study results.
Oral decitabine cedazuridine...
02/21/2024
Oncology
News
Assessment of Individualized MRD With NGS, ddPCR Effective for Early Detection of MDS Relapse
02/09/2024

Amber Denham

Amber Denham
Evaluating individualized measurable residual disease with next-generation sequencing and droplet digital polymerase chain reaction is feasible and can be used for early detection of relapse among patients with myelodysplastic syndrome,...
Evaluating individualized measurable residual disease with next-generation sequencing and droplet digital polymerase chain reaction is feasible and can be used for early detection of relapse among patients with myelodysplastic syndrome,...
Evaluating individualized...
02/09/2024
Oncology
News
Efficacy of Azacitidine Among Treatment-Naive Patients With Higher-Risk Myelodysplastic Syndromes
01/31/2024

Amber Denham

Amber Denham
Azacitidine demonstrated low complete remission rates and low median overall survival as a frontline therapy for patients with high-risk myelodysplastic syndromes, according to a retrospective study.
Azacitidine demonstrated low complete remission rates and low median overall survival as a frontline therapy for patients with high-risk myelodysplastic syndromes, according to a retrospective study.
Azacitidine demonstrated low...
01/31/2024
Oncology
News
Sabatolimab Plus Hypomethylating Agents as Frontline Therapy for Patients With Higher-Risk MDS
01/11/2024

Amber Denham

Amber Denham
A phase 2 trial determined that the addition of sabatolimab to hypomethylating agents showed manageable safety, but did not result in a significant improvement in complete response rates or progression-free survival for untreated patients...
A phase 2 trial determined that the addition of sabatolimab to hypomethylating agents showed manageable safety, but did not result in a significant improvement in complete response rates or progression-free survival for untreated patients...
A phase 2 trial determined that...
01/11/2024
Oncology
Quiz
Eltrombopag for Low-Risk Myelodysplastic Syndromes and Severe Thrombocytopenia
01/05/2024
True or False: Results from the phase 2 EQOL-MDS trial indicated that patients who received eltrombopag demonstrated a higher platelet response and less frequent significant bleeding compared to patients who received a placebo.
True or False: Results from the phase 2 EQOL-MDS trial indicated that patients who received eltrombopag demonstrated a higher platelet response and less frequent significant bleeding compared to patients who received a placebo.
True or False: Results from the...
01/05/2024
Oncology
Conference Coverage
Fedratinib Demonstrates Promising Efficacy in MDS/MPN and Chronic Neutrophilic Leukemia
12/09/2023

Janelle Bradley

Janelle Bradley
Data from a phase 2 trial show fedratinib demonstrates promising clinical activity in patients with MDS/MPN and chronic neutrophilic leukemia.
Data from a phase 2 trial show fedratinib demonstrates promising clinical activity in patients with MDS/MPN and chronic neutrophilic leukemia.
Data from a phase 2 trial show...
12/09/2023
Oncology
Conference Coverage
Phase 3 IMerge Study Confirms Clinical Efficacy of Imetelstat in Lower-Risk MDS Across Risk Categories
12/09/2023

Janelle Bradley

Janelle Bradley
Imetelstat improves red blood cell transfusion independence rates vs placebo in patients with lower-risk MDS relapsed/refractory to erythropoiesis-stimulating agents across different subgroups, according to data from the IMerge phase 3 study.
Imetelstat improves red blood cell transfusion independence rates vs placebo in patients with lower-risk MDS relapsed/refractory to erythropoiesis-stimulating agents across different subgroups, according to data from the IMerge phase 3 study.
Imetelstat improves red blood...
12/09/2023
Oncology
News
Molecular Scoring System IPSS-M Demonstrates Superior Predictive Potential for Survival and AML Transformation Among Patients With MDS
10/30/2023

Jordan Kadish

Jordan Kadish
Molecular scoring system IPSS-M demonstrated superior accuracy in predicting survival outcomes and acute myeloid leukemia transformation compared to IPSS-R among patients with myelodysplastic syndrome.
Molecular scoring system IPSS-M demonstrated superior accuracy in predicting survival outcomes and acute myeloid leukemia transformation compared to IPSS-R among patients with myelodysplastic syndrome.
Molecular scoring system IPSS-M...
10/30/2023
Oncology

News

News
FDA Grants Approval to Imetelstat for Patients With Low to Intermediate-1 Risk Myelodysplastic Syndrome With Transfusion-Dependent Anemia
06/21/2024
The FDA granted approval to imetelstat for patients with low to intermediate-1 risk MDS with transfusion-dependent anemia requiring 4 or more red blood cell transfusion units over 8 weeks, who cannot derive benefit from...
The FDA granted approval to imetelstat for patients with low to intermediate-1 risk MDS with transfusion-dependent anemia requiring 4 or more red blood cell transfusion units over 8 weeks, who cannot derive benefit from...
The FDA granted approval to...
06/21/2024
Oncology
News
Azacitidine Maintenance Demonstrates Lower Disease Progression Rate Among Patients With High-Risk FLT3-Negative AML/MDS
03/05/2024

Amber Denham

Amber Denham
According to a retrospective analysis, azacitidine maintenance is associated with a lower progression rate in patients with high-risk FLT3-negative acute myeloid leukemia or myelodysplastic syndrome.
According to a retrospective analysis, azacitidine maintenance is associated with a lower progression rate in patients with high-risk FLT3-negative acute myeloid leukemia or myelodysplastic syndrome.
According to a retrospective...
03/05/2024
Oncology
News
Oral Decitabine Cedazuridine Safe, Effective Alternative to Intravenous Decitabine for Patients With MDS or CML
02/21/2024

Amber Denham

Amber Denham
Oral decitabine cedazuridine demonstrates safety and efficacy as an alternative to intravenous decitabine treatment among patients with myelodysplastic syndromes or chronic myelomonocytic leukemia, according to phase 3 study results.
Oral decitabine cedazuridine demonstrates safety and efficacy as an alternative to intravenous decitabine treatment among patients with myelodysplastic syndromes or chronic myelomonocytic leukemia, according to phase 3 study results.
Oral decitabine cedazuridine...
02/21/2024
Oncology
News
Assessment of Individualized MRD With NGS, ddPCR Effective for Early Detection of MDS Relapse
02/09/2024

Amber Denham

Amber Denham
Evaluating individualized measurable residual disease with next-generation sequencing and droplet digital polymerase chain reaction is feasible and can be used for early detection of relapse among patients with myelodysplastic syndrome,...
Evaluating individualized measurable residual disease with next-generation sequencing and droplet digital polymerase chain reaction is feasible and can be used for early detection of relapse among patients with myelodysplastic syndrome,...
Evaluating individualized...
02/09/2024
Oncology
News
Efficacy of Azacitidine Among Treatment-Naive Patients With Higher-Risk Myelodysplastic Syndromes
01/31/2024

Amber Denham

Amber Denham
Azacitidine demonstrated low complete remission rates and low median overall survival as a frontline therapy for patients with high-risk myelodysplastic syndromes, according to a retrospective study.
Azacitidine demonstrated low complete remission rates and low median overall survival as a frontline therapy for patients with high-risk myelodysplastic syndromes, according to a retrospective study.
Azacitidine demonstrated low...
01/31/2024
Oncology
News
Sabatolimab Plus Hypomethylating Agents as Frontline Therapy for Patients With Higher-Risk MDS
01/11/2024

Amber Denham

Amber Denham
A phase 2 trial determined that the addition of sabatolimab to hypomethylating agents showed manageable safety, but did not result in a significant improvement in complete response rates or progression-free survival for untreated patients...
A phase 2 trial determined that the addition of sabatolimab to hypomethylating agents showed manageable safety, but did not result in a significant improvement in complete response rates or progression-free survival for untreated patients...
A phase 2 trial determined that...
01/11/2024
Oncology
Conference Coverage
Fedratinib Demonstrates Promising Efficacy in MDS/MPN and Chronic Neutrophilic Leukemia
12/09/2023

Janelle Bradley

Janelle Bradley
Data from a phase 2 trial show fedratinib demonstrates promising clinical activity in patients with MDS/MPN and chronic neutrophilic leukemia.
Data from a phase 2 trial show fedratinib demonstrates promising clinical activity in patients with MDS/MPN and chronic neutrophilic leukemia.
Data from a phase 2 trial show...
12/09/2023
Oncology
Conference Coverage
Phase 3 IMerge Study Confirms Clinical Efficacy of Imetelstat in Lower-Risk MDS Across Risk Categories
12/09/2023

Janelle Bradley

Janelle Bradley
Imetelstat improves red blood cell transfusion independence rates vs placebo in patients with lower-risk MDS relapsed/refractory to erythropoiesis-stimulating agents across different subgroups, according to data from the IMerge phase 3 study.
Imetelstat improves red blood cell transfusion independence rates vs placebo in patients with lower-risk MDS relapsed/refractory to erythropoiesis-stimulating agents across different subgroups, according to data from the IMerge phase 3 study.
Imetelstat improves red blood...
12/09/2023
Oncology
News
Molecular Scoring System IPSS-M Demonstrates Superior Predictive Potential for Survival and AML Transformation Among Patients With MDS
10/30/2023

Jordan Kadish

Jordan Kadish
Molecular scoring system IPSS-M demonstrated superior accuracy in predicting survival outcomes and acute myeloid leukemia transformation compared to IPSS-R among patients with myelodysplastic syndrome.
Molecular scoring system IPSS-M demonstrated superior accuracy in predicting survival outcomes and acute myeloid leukemia transformation compared to IPSS-R among patients with myelodysplastic syndrome.
Molecular scoring system IPSS-M...
10/30/2023
Oncology
News
FDA Grants Approval to Ivosidenib for Patients With R/R Myelodysplastic Syndromes With IDH1 Mutation
10/26/2023

Jordan Kadish

Jordan Kadish
On October 24, 2023, the FDA granted approval for ivosidenib, a small molecule inhibitor of IDH1, in the treatment of patients with R/R myelodysplastic syndromes with IDH1 mutation.
On October 24, 2023, the FDA granted approval for ivosidenib, a small molecule inhibitor of IDH1, in the treatment of patients with R/R myelodysplastic syndromes with IDH1 mutation.
On October 24, 2023, the FDA...
10/26/2023
Oncology
News
Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation
08/08/2024
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study...
08/08/2024
Oncology
FDA Approval
FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma
08/08/2024
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug...
08/08/2024
Oncology
News
Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer
08/07/2024
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the...
08/07/2024
Oncology
News
Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL
08/07/2024
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that...
08/07/2024
Oncology
News
Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer
08/07/2024
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study...
08/07/2024
Oncology
FDA Approval
FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma
08/06/2024
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO...
08/06/2024
Oncology
Nirav Shah, MD
Videos
Innovation and the Future Development of Cell Therapies for Patients With B-Cell Lymphomas
08/05/2024
At the 2024 Pan Pacific Lymphoma Conference, Nirav Shah, MD, discusses innovation and the future development of cell therapies for patients with various types of B-cell malignancies.
At the 2024 Pan Pacific Lymphoma Conference, Nirav Shah, MD, discusses innovation and the future development of cell therapies for patients with various types of B-cell malignancies.
At the 2024 Pan Pacific Lymphoma...
08/05/2024
Oncology
Curtis Lachowiez, MD
Videos
Exploring Triplet Therapy for Patients With AML Ineligible for Intensive Induction Chemotherapy
08/05/2024
Curtis Lachowiez, MD, participated in a debate at the 2024 Great Debates and Updates meeting in which he argued in favor of triplet therapy for patients with acute myeloid leukemia who are unable to receive intensive induction chemotherapy.
Curtis Lachowiez, MD, participated in a debate at the 2024 Great Debates and Updates meeting in which he argued in favor of triplet therapy for patients with acute myeloid leukemia who are unable to receive intensive induction chemotherapy.
Curtis Lachowiez, MD,...
08/05/2024
Oncology
FDA Approval
FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma
08/02/2024
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food...
08/02/2024
Oncology
Rene Adam, MD, PhD
Conference Coverage
Chemotherapy and Liver Transplantation for Patients With Unresectable Colorectal Liver Metastases
08/02/2024
Rene Adam, MD, PhD, discusses results from the TRANSMET trial which demonstrated that liver transplantation combined with chemotherapy significantly improved survival among patients with unresectable colorectal liver metastases.
Rene Adam, MD, PhD, discusses results from the TRANSMET trial which demonstrated that liver transplantation combined with chemotherapy significantly improved survival among patients with unresectable colorectal liver metastases.
Rene Adam, MD, PhD, discusses...
08/02/2024
Oncology

Interactive Features

Quiz
Safety of Oral Decitabine Cedazuridine vs Intravenous Decitabine for Patients With MDS or CML
06/02/2024
06/02/2024
Oncology
Quiz
Eltrombopag for Low-Risk Myelodysplastic Syndromes and Severe Thrombocytopenia
01/05/2024
True or False: Results from the phase 2 EQOL-MDS trial indicated that patients who received eltrombopag demonstrated a higher platelet response and less frequent significant bleeding compared to patients who received a placebo.
True or False: Results from the phase 2 EQOL-MDS trial indicated that patients who received eltrombopag demonstrated a higher platelet response and less frequent significant bleeding compared to patients who received a placebo.
True or False: Results from the...
01/05/2024
Oncology
Quiz
Haploidentical Donors vs Matched Unrelated Donors for High-Risk MDS
06/09/2023
True or False: In a retrospective multicenter study on the use of haploidentical donors for treatment of high-risk MDS, results indicated that overall survival and progression-free survival were significantly higher among patients who...
True or False: In a retrospective multicenter study on the use of haploidentical donors for treatment of high-risk MDS, results indicated that overall survival and progression-free survival were significantly higher among patients who...
True or False: In a...
06/09/2023
Oncology
Quiz
Quiz: Post-Transplant Eprenetapopt and Azacitidine Maintenance in TP53-Mutant AML and MDS
10/05/2022
True or False: In a recent phase 2 trial, post-transplant eprenetapopt and azacitidine maintenance demonstrated promising safety and efficacy in TP53-mutant acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
True or False: In a recent phase 2 trial, post-transplant eprenetapopt and azacitidine maintenance demonstrated promising safety and efficacy in TP53-mutant acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
True or False: In a recent phase...
10/05/2022
Oncology
Quiz
Maintenance Selinexor for Patients With Advanced or First-Line Recurrent TP53 Wild-Type Endometrial Cancer
08/08/2024
Do you know whether maintenance selinexor demonstrated promising efficacy and safety among patients with advanced or first-line recurrent TP53 wild-type endometrial cancer?
Do you know whether maintenance selinexor demonstrated promising efficacy and safety among patients with advanced or first-line recurrent TP53 wild-type endometrial cancer?
Do you know whether maintenance...
08/08/2024
Oncology
Quiz
Recommended Dostarlimab Dose for Patients With Primary Advanced or Recurrent Endometrial Cancer
08/08/2024
Based on results from the phase 3 RUBY trial, the FDA expanded the approval of dostarlimab plus chemotherapy to include all patients with primary advanced or recurrent endometrial cancer. Do you know what the recommended dose of dostarlimab...
Based on results from the phase 3 RUBY trial, the FDA expanded the approval of dostarlimab plus chemotherapy to include all patients with primary advanced or recurrent endometrial cancer. Do you know what the recommended dose of dostarlimab...
Based on results from the phase...
08/08/2024
Oncology
Quiz
Everolimus Plus Endocrine Therapy for Patients With Early Breast Cancer
08/05/2024
True or False: According to results from the phase 3 SWOG S127 study, the addition of everolimus, an mTOR inhibitor, to endocrine therapy did not improve survival outcomes among patients with high-risk, hormone receptor (HR)-positive,...
True or False: According to results from the phase 3 SWOG S127 study, the addition of everolimus, an mTOR inhibitor, to endocrine therapy did not improve survival outcomes among patients with high-risk, hormone receptor (HR)-positive,...
True or False: According to...
08/05/2024
Oncology
Quiz
Improving Long-Term Outcomes for Patients With HER2-Positive Early-Stage Invasive Breast Cancer
07/15/2024
According to the final analysis of the phase 2 ATEMPT trial, which of the following therapies demonstrated more favorable long-term outcomes among patients with HER2-positive early-stage invasive breast cancer?
According to the final analysis of the phase 2 ATEMPT trial, which of the following therapies demonstrated more favorable long-term outcomes among patients with HER2-positive early-stage invasive breast cancer?
According to the final analysis...
07/15/2024
Oncology
Quiz
Ibrutinib Plus Venetoclax For Patients With TP53-Mutated Mantle Cell Lymphoma
07/12/2024
07/12/2024
Oncology
Quiz
Weekly Combination Therapy for Patients With R/R Multiple Myeloma
07/11/2024
07/11/2024
Oncology
Quiz
Examining the Efficacy of Azacitidine Plus Ruxolitinib in Myelofibrosis Treatment
07/03/2024
07/03/2024
Oncology
Quiz
FDA Approval of Lisocabtagene Maraleucel for MCL
07/01/2024
07/01/2024
Oncology
Quiz
Carboplatin Plus Standard Chemotherapy for Patients With Early-Stage Triple-Negative Breast Cancer
06/28/2024
True or False: As reported in the phase 3 PEARLY trial, the addition of carboplatin to standard anthracycline and taxane therapy significantly improved event-free survival among patients with early-stage triple-negative breast cancer (TNBC).
True or False: As reported in the phase 3 PEARLY trial, the addition of carboplatin to standard anthracycline and taxane therapy significantly improved event-free survival among patients with early-stage triple-negative breast cancer (TNBC).
True or False: As reported in...
06/28/2024
Oncology
Quiz
Treatment Options for a Patient With Early-Stage Non-Small Cell Lung Cancer
06/26/2024
What adjuvant treatment would you recommend?
What adjuvant treatment would you recommend?
What adjuvant treatment would...
06/26/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Recent News

News
FDA Grants Approval to Imetelstat for Patients With Low to Intermediate-1 Risk Myelodysplastic Syndrome With Transfusion-Dependent Anemia
06/21/2024
The FDA granted approval to imetelstat for patients with low to intermediate-1 risk MDS with transfusion-dependent anemia requiring 4 or more red blood cell transfusion units over 8 weeks, who cannot derive benefit from...
The FDA granted approval to imetelstat for patients with low to intermediate-1 risk MDS with transfusion-dependent anemia requiring 4 or more red blood cell transfusion units over 8 weeks, who cannot derive benefit from...
The FDA granted approval to...
06/21/2024
Oncology
News
Azacitidine Maintenance Demonstrates Lower Disease Progression Rate Among Patients With High-Risk FLT3-Negative AML/MDS
03/05/2024

Amber Denham

Amber Denham
According to a retrospective analysis, azacitidine maintenance is associated with a lower progression rate in patients with high-risk FLT3-negative acute myeloid leukemia or myelodysplastic syndrome.
According to a retrospective analysis, azacitidine maintenance is associated with a lower progression rate in patients with high-risk FLT3-negative acute myeloid leukemia or myelodysplastic syndrome.
According to a retrospective...
03/05/2024
Oncology
News
Oral Decitabine Cedazuridine Safe, Effective Alternative to Intravenous Decitabine for Patients With MDS or CML
02/21/2024

Amber Denham

Amber Denham
Oral decitabine cedazuridine demonstrates safety and efficacy as an alternative to intravenous decitabine treatment among patients with myelodysplastic syndromes or chronic myelomonocytic leukemia, according to phase 3 study results.
Oral decitabine cedazuridine demonstrates safety and efficacy as an alternative to intravenous decitabine treatment among patients with myelodysplastic syndromes or chronic myelomonocytic leukemia, according to phase 3 study results.
Oral decitabine cedazuridine...
02/21/2024
Oncology
News
Assessment of Individualized MRD With NGS, ddPCR Effective for Early Detection of MDS Relapse
02/09/2024

Amber Denham

Amber Denham
Evaluating individualized measurable residual disease with next-generation sequencing and droplet digital polymerase chain reaction is feasible and can be used for early detection of relapse among patients with myelodysplastic syndrome,...
Evaluating individualized measurable residual disease with next-generation sequencing and droplet digital polymerase chain reaction is feasible and can be used for early detection of relapse among patients with myelodysplastic syndrome,...
Evaluating individualized...
02/09/2024
Oncology
News
Efficacy of Azacitidine Among Treatment-Naive Patients With Higher-Risk Myelodysplastic Syndromes
01/31/2024

Amber Denham

Amber Denham
Azacitidine demonstrated low complete remission rates and low median overall survival as a frontline therapy for patients with high-risk myelodysplastic syndromes, according to a retrospective study.
Azacitidine demonstrated low complete remission rates and low median overall survival as a frontline therapy for patients with high-risk myelodysplastic syndromes, according to a retrospective study.
Azacitidine demonstrated low...
01/31/2024
Oncology
News
Sabatolimab Plus Hypomethylating Agents as Frontline Therapy for Patients With Higher-Risk MDS
01/11/2024

Amber Denham

Amber Denham
A phase 2 trial determined that the addition of sabatolimab to hypomethylating agents showed manageable safety, but did not result in a significant improvement in complete response rates or progression-free survival for untreated patients...
A phase 2 trial determined that the addition of sabatolimab to hypomethylating agents showed manageable safety, but did not result in a significant improvement in complete response rates or progression-free survival for untreated patients...
A phase 2 trial determined that...
01/11/2024
Oncology
Conference Coverage
Fedratinib Demonstrates Promising Efficacy in MDS/MPN and Chronic Neutrophilic Leukemia
12/09/2023

Janelle Bradley

Janelle Bradley
Data from a phase 2 trial show fedratinib demonstrates promising clinical activity in patients with MDS/MPN and chronic neutrophilic leukemia.
Data from a phase 2 trial show fedratinib demonstrates promising clinical activity in patients with MDS/MPN and chronic neutrophilic leukemia.
Data from a phase 2 trial show...
12/09/2023
Oncology
Conference Coverage
Phase 3 IMerge Study Confirms Clinical Efficacy of Imetelstat in Lower-Risk MDS Across Risk Categories
12/09/2023

Janelle Bradley

Janelle Bradley
Imetelstat improves red blood cell transfusion independence rates vs placebo in patients with lower-risk MDS relapsed/refractory to erythropoiesis-stimulating agents across different subgroups, according to data from the IMerge phase 3 study.
Imetelstat improves red blood cell transfusion independence rates vs placebo in patients with lower-risk MDS relapsed/refractory to erythropoiesis-stimulating agents across different subgroups, according to data from the IMerge phase 3 study.
Imetelstat improves red blood...
12/09/2023
Oncology
News
Molecular Scoring System IPSS-M Demonstrates Superior Predictive Potential for Survival and AML Transformation Among Patients With MDS
10/30/2023

Jordan Kadish

Jordan Kadish
Molecular scoring system IPSS-M demonstrated superior accuracy in predicting survival outcomes and acute myeloid leukemia transformation compared to IPSS-R among patients with myelodysplastic syndrome.
Molecular scoring system IPSS-M demonstrated superior accuracy in predicting survival outcomes and acute myeloid leukemia transformation compared to IPSS-R among patients with myelodysplastic syndrome.
Molecular scoring system IPSS-M...
10/30/2023
Oncology
News
FDA Grants Approval to Ivosidenib for Patients With R/R Myelodysplastic Syndromes With IDH1 Mutation
10/26/2023

Jordan Kadish

Jordan Kadish
On October 24, 2023, the FDA granted approval for ivosidenib, a small molecule inhibitor of IDH1, in the treatment of patients with R/R myelodysplastic syndromes with IDH1 mutation.
On October 24, 2023, the FDA granted approval for ivosidenib, a small molecule inhibitor of IDH1, in the treatment of patients with R/R myelodysplastic syndromes with IDH1 mutation.
On October 24, 2023, the FDA...
10/26/2023
Oncology
News
Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation
08/08/2024
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study...
08/08/2024
Oncology
FDA Approval
FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma
08/08/2024
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug...
08/08/2024
Oncology
News
Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer
08/07/2024
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the...
08/07/2024
Oncology
News
Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL
08/07/2024
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that...
08/07/2024
Oncology
News
Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer
08/07/2024
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study...
08/07/2024
Oncology
FDA Approval
FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma
08/06/2024
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO...
08/06/2024
Oncology
FDA Approval
FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma
08/02/2024
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food...
08/02/2024
Oncology
FDA Approval
FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer
08/01/2024
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab...
08/01/2024
Oncology
News
Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML
08/01/2024
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of...
08/01/2024
Oncology
News
Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
08/01/2024
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the...
08/01/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use

Advertisement

Advertisement